Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Is this the end for Cas­sa­va Sci­ences?

Af­ter a prob­lem­at­ic de­vel­op­ment path rid­dled with al­le­ga­tions of mis­lead­ing in­vestors, the biotech’s Alzheimer’s drug flopped on all …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER